- Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday,.
As of late, it has definitely been a great time to be an investor Autolus Therapeutics
Autolus Therapeutics plc (AUTL) today announced additional data regarding its ongoing Phase 1/2 clinical trial of its next-generation programmed T cell therapy, AUTO3, to treat adults with relapsed/refractory diffuse large B cell lymphoma (DLBCL). The data is to be presented in a keynote lecture titled “Improved CAR T cell approaches for lymphoid malignancies,” by Dr. Martin Pulé, clinical senior lecturer in the Dept. of Hematology at UCL Cancer Institute and chief scientific officer of Autolus Therapeutics, at the EHA-EBMT 2nd European CAR T Cell Meeting to be held on January 30, 2020 at 17:15 P.M. CET in Stiges (Barcelona), Spain.
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be viewed and downloaded from www.autolus.com. The Notice states that the AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST (8.00 am EDT) on Thursday, June 18, 2020. In order to ensure that our AGM may proceed on Thursday, June 18, 2020 in compliance with the Stay at Home Measures, arrangements have been made for a quorum of two shareholders only to be present at our AGM this year.
AUTL earnings call for the period ending March 31, 2020.
- Preclinical data on AUTO5 in T cell lymphoma and solid tumor data on AUTO6NG in small cell lung cancer and AUTO7 in prostate cancer - Conference Call and Webcast to be held.
- Conference Call to be held on May 7, 2020 at 8:30 am EDT/1:30 pm BST- LONDON, May 07, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical.
LONDON, May 01, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
It's been a pretty great week for Autolus Therapeutics plc (NASDAQ:AUTL) shareholders, with its shares surging 12% to...
- Conference call to be held on March 3, 2020 at 8:30 am EST/1:30 pm GMT - LONDON, March 03, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage.
LONDON, May 26, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
LONDON, Feb. 24, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
Autolus Therapeutics (AUTL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announces that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for AUTO1, its lead CAR T product candidate for the treatment of adults with acute lymphoblastic leukemia (ALL). The active IND allows initiation of the US sites in the company’s first pivotal study, AUTO1-AL1. The AUTO1-AL1 study clinical trial application was approved by the MHRA in January 2020 and the first site opened in the UK in March of this year.
LONDON, Feb. 25, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the closing of its previously announced underwritten public offering of American Depositary Shares (“ADSs”) in the United States. Autolus sold 7,250,000 ADSs representing 7,250,000 ordinary shares at a public offering price of $11.00 per ADS. Autolus has also granted the underwriters a 30-day option to purchase up to an additional 1,087,500 ADSs at the public offering price, less underwriting discounts and commissions.
Autolus Therapeutics PLC Sponsored ADR (AUTL) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Shares of Autolus Therapeutics (NASDAQ:AUTL) were unchanged at $10.28 after the company reported Q1 results.Quarterly Results Earnings per share rose 13.04% year over year to ($0.60), which beat the estimate of ($0.74).Revenue of $338,000 lower by 82.79% year over year, which missed the estimate of $600,000.Guidance Earnings guidance hasn't been issued by the company for now.Autolus Therapeutics hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 07, 2020View more earnings on AUTLTime: 09:05 PM ETWebcast URL: https://edge.media-server.com/mmc/p/ymhc6n4qPrice Action Company's 52-week high was at $25.90Company's 52-week low was at $3.00Price action over last quarter: Up 10.66%Company Description Autolus Therapeutics PLC is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and others.See more from Benzinga * World Acceptance: Q4 Earnings Insights * Donnelley Financial Solutions: Q1 Earnings Insights * Xeris Pharmaceuticals: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call.